The Successful Treatment of COVID-19-Induced Bullous Pemphigoid With Dupilumab

Bullous pemphigoid (BP) is a rare autoimmune blistering condition that predominantly affects the elderly population. Typical treatment regimens target the immune system and inflammatory response. We present a case of BP in a 78-year-old male patient that occurred following the coronavirus disease 20...

Descripción completa

Detalles Bibliográficos
Autores principales: Savoldy, Michelle A, Tadicherla, Teja, Moureiden, Zade, Ayoubi, Noura, Baldwin, Brooke T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Dermatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675981/
https://www.ncbi.nlm.nih.gov/pubmed/36415388
http://dx.doi.org/10.7759/cureus.30541
Descripción
Sumario:Bullous pemphigoid (BP) is a rare autoimmune blistering condition that predominantly affects the elderly population. Typical treatment regimens target the immune system and inflammatory response. We present a case of BP in a 78-year-old male patient that occurred following the coronavirus disease 2019 (COVID-19) vaccination. This case was refractory to topical steroids and immunosuppressants. However, it responded to treatment with dupilumab, a monoclonal antibody therapy. Dupilumab is classically indicated for the treatment of asthma, eosinophilic esophagitis, atopic dermatitis, and chronic rhinosinusitis with nasal polyposis. We highlight the importance of considering the off-label use of dupilumab and its success in treating BP.

Ejemplares similares